Security Snapshot

Wave Life Sciences, Inc. - Common Stock (WVE) Institutional Ownership

CUSIP: Y95308105

13F Institutional Holders and Ownership History from Q4 2015 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

2

Shares (Excl. Options)

1.07KFull value: 1,065 · shares · 30 Sep 2026

Price

$4.30

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-65,458,430
Value change
-$380,361,923
Number of holders
2
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
188,679,245
SEC-reported price per share
$4.30
Insider filing price
$4.30
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • WVE - Wave Life Sciences, Inc. - Common Stock is tracked under CUSIP Y95308105.
  • 2 institutions reported positions in Q3 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 237 to 2 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.06BFull value: $1,058,382,452 · USD · 30 Jun 2026
    to
    $4.83KFull value: $4,832 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 2 institutions filings for Q3 2026.

Open SEC evidence

Security key

Y95308105

13F reference period

Q3 2026

13F holders

2

13D/G owners

4

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
WVE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 17% -2.2% $248,138,341 34,225,506 0% RA Capital Management, L.P. 15 Apr 2026
MAVERICK CAPITAL LTD 5.4% $56,093,833 8,261,242 Maverick Capital, Ltd. 31 Dec 2024
FMR LLC 2.8% -63% $37,284,027 -$70,566,627 5,192,761 -65% FMR LLC 31 Mar 2026
Adage Capital Management, L.P. 0.53% -96% $7,180,000 -$63,083,918 1,000,000 -90% Adage Capital Management, L.P. 31 Mar 2026
As of 30 Sep 2026, 2 institutional investors reported holding
1.07KFull value: 1,065 · shares · 30 Sep 2026
shares of Wave Life Sciences, Inc. - Common Stock (WVE). This represents 0% of the company’s total
188.68MFull value: 188,679,245 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
44
Headline period
Q3 2026
Rows shown
1-25 of 44
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 1,065 $4,832 -$380,361,923 $4.30 2
2026 Q2 182,171,491 $1,058,382,452 +$41,131,513 $5.81 237
2026 Q1 172,515,421 $1,247,622,486 -$203,603,859 $7.25 229
2025 Q4 182,758,989 $3,108,295,726 +$421,681,651 $17.00 219
2025 Q3 143,680,189 $1,051,640,675 +$37,184,597 $7.32 187
2025 Q2 138,939,054 $903,136,388 +$46,387,682 $6.50 174
2025 Q1 131,293,097 $1,061,209,645 +$20,316,471 $8.08 192
2024 Q4 128,616,529 $1,591,015,441 +$86,595,360 $12.37 181
2024 Q3 120,246,621 $986,101,781 +$176,011,863 $8.20 160
2024 Q2 95,071,148 $474,405,111 +$9,854,270 $4.99 143
2024 Q1 92,759,614 $572,308,103 +$4,033,614 $6.17 131
2023 Q4 92,528,153 $468,029,084 +$93,144,169 $5.05 115
2023 Q3 72,598,087 $417,436,128 +$3,006,886 $5.75 85
2023 Q2 72,147,137 $262,614,478 +$6,429,830 $3.64 80
2023 Q1 70,086,593 $303,466,627 +$3,780,454 $4.33 72
2022 Q4 68,108,089 $476,736,473 +$7,420,705 $7.00 74
2022 Q3 67,256,615 $242,816,542 -$1,613,831 $3.61 58
2022 Q2 67,784,074 $220,297,785 +$69,127,143 $3.25 56
2022 Q1 47,551,964 $95,097,268 -$1,035,989 $2.00 77
2021 Q4 47,284,486 $148,479,513 +$13,347,500 $3.14 87
2021 Q3 37,428,616 $183,549,240 +$443,975 $4.90 84
2021 Q2 37,041,603 $246,689,021 -$5,849,970 $6.66 82
2021 Q1 38,281,847 $214,782,368 +$1,495,724 $5.61 97
2020 Q4 36,092,793 $284,070,815 -$9,567,182 $7.87 102
2020 Q3 37,117,728 $315,928,313 +$59,335,508 $8.49 106
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .